Target Price | $25.00 |
Price | $21.47 |
Potential |
16.44%
register free of charge
|
Number of Estimates | 4 |
4 Analysts have issued a price target ADMA Biologics, Inc. 2025 .
The average ADMA Biologics, Inc. target price is $25.00.
This is
16.44%
register free of charge
$26.00
21.10%
register free of charge
$24.00
11.78%
register free of charge
|
|
A rating was issued by 5 analysts: 5 Analysts recommend ADMA Biologics, Inc. to buy, 0 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the ADMA Biologics, Inc. stock has an average upside potential 2025 of
16.44%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 258.22 | 422.30 |
67.59% | 63.54% | |
EBITDA Margin | 11.60% | 39.32% |
155.07% | 238.89% | |
Net Margin | -11.90% | 27.99% |
76.49% | 335.20% |
4 Analysts have issued a sales forecast ADMA Biologics, Inc. 2024 . The average ADMA Biologics, Inc. sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an ADMA Biologics, Inc. EBITDA forecast 2024. The average ADMA Biologics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
3 ADMA Biologics, Inc. Analysts have issued a net profit forecast 2024. The average ADMA Biologics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -0.13 | 0.50 |
60.61% | 484.62% | |
P/E | 42.94 | |
EV/Sales | 12.08 |
3 Analysts have issued a ADMA Biologics, Inc. forecast for earnings per share. The average ADMA Biologics, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the ADMA Biologics, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
ADMA Biologics, Inc....
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.